Immune niches in brain metastases contain TCF1+ stem-like T cells, are associated with disease control and are modulated by preoperative SRS

Abstract The CD8 + T-cell response is prognostic for survival outcomes in several tumor types. However, whether this extends to tumors in the brain, an organ with barriers to T cell entry, remains unclear. Here, we analyzed immune infiltration in 67 brain metastasis (BrM) and found high frequencies of PD1 + TCF1 + stem-like CD8 + T-cells and TCF1- effector-like cells. Importantly, the stem-like cells aggregate with antigen presenting cells in immune niches, and niches were prognostic for local disease control. Standard of care for BrM is resection followed by stereotactic radiosurgery (SRS), so to determine SRS’s impact on the BrM immune response, we examined 76 BrM treated with pre-operative SRS (pSRS). pSRS acutely reduced CD8 + T cells at 3 days. However, CD8 + T cells rebounded by day 6, driven by increased frequency of effector-like cells. This suggests that the immune response in BrM can be regenerated rapidly, likely by the local TCF1 + stem-like population.

[1]  Evan Z. Macosko,et al.  Dissecting the treatment-naive ecosystem of human melanoma brain metastasis , 2022, Cell.

[2]  S. Ramalingam,et al.  Distinct phenotypic states and spatial distribution of CD8+ T cell clonotypes in human brain metastases , 2022, Cell reports. Medicine.

[3]  Z. Werb,et al.  Cellular architecture of human brain metastases , 2021, Cell.

[4]  C. Brennan,et al.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells , 2020, Cell.

[5]  B. Becher,et al.  Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes , 2020, Cell.

[6]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.

[7]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.

[8]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[9]  B. Bender,et al.  Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases , 2015, Oncotarget.

[10]  M. Schwartz,et al.  Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates , 2013, Nature Reviews Immunology.

[11]  B. Engelhardt,et al.  Capture, crawl, cross: the T cell code to breach the blood-brain barriers. , 2012, Trends in immunology.

[12]  B. Engelhardt,et al.  The anatomical and cellular basis of immune surveillance in the central nervous system , 2012, Nature Reviews Immunology.

[13]  F. Charron,et al.  The Hedgehog Pathway Promotes Blood-Brain Barrier Integrity and CNS Immune Quiescence , 2011, Science.

[14]  D. Kondziolka,et al.  The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[15]  Michael Detmar,et al.  A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules , 2015 .